Indiana Alzheimer Disease Center

Neuroimaging Core

The Neuroimaging Core of the Indiana Alzheimer’s Disease Center serves as a regional and national resource for the aging and neurodegeneration research community—spanning academia, health care and pharmaceutical industry. The core provides access to and collaborative support for the application of advanced neuroimaging in clinical and translational research.

The Neuroimaging Core is developing and implementing advanced imaging protocols and imaging-genetics analysis techniques, collaborating with NIA-funded initiatives, including ADNI, DIAN and ADGC. The core also provides training in neuroimaging and imaging genetics to scientists of all levels (undergraduate to faculty) and disciplines (neuroscience, genetics, computer science, physicians, and more).


Support funded research in the center, IU Center for Aging Research, and related programs that currently employ or could benefit from advanced neuroimaging.

Provide standardized, state-of-the-art neuroimaging acquisition and analysis protocols

Expand transdisciplinary regional neuroscience research using advanced neuroimaging tools to study disease mechanisms and treatments for neurodegeneration

Support and collaborate with major national and international Alzheimer’s Disease-related research consortia using neuroimaging and genetics methods.

Provide transdisciplinary educational opportunities in neuroimaging and genetics of Alzheimer’s disease and other degenerative disorders for basic and clinical scientists at all levels—from undergraduates to post-doctoral fellows and faculty—and disseminate neuroimaging results to the community.

Imaging Services

The Neuroimaging Core, working closely with the Clinical Core, performs state-of-the-art advanced multimodal MRI (Siemens Prisma 3T: high resolution structural and 3D pCASL perfusion, multiband resting-state and task-based fMRI, and DTI optimized for structural and functional connectome analysis) on all eligible Indiana Alzheimer’s Disease Center participants as well as amyloid and/or tau PET on 225 IADC participants.

Participants in preclinical or early symptomatic phases (e.g., subjective cognitive decline or with mild cognitive impairment), late-onset Alzheimer’s disease, and individuals from families with mutations causal for dementias are prioritized.

Imaging-pathologic correlation, when available, improves understanding of early structural, functional and molecular changes observed in vivo and may help identify novel therapeutic targets. Cross-modality image analyses and results of imaging genetics studies with ADNI, DIAN and other partners contribute to advances in early detection, mechanistic understanding, and optimized use of imaging as a dynamic biomarker for the study of therapeutic effects.

Acquiring standardized state-of-the-art MRI and PET data for use by many investigators increase research productivity and facilitate the optimized quantitative analyses.

Close integration with other cores further allow the Indiana Alzheimer’s Disease Center to expand on these analyses by relating imaging biomarkers to neuropsychological measures, neuropathologic samples, genetic and other –omics markers.